Welcome to our dedicated page for Bio-Path Holdings news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Holdings stock.
Bio-Path Holdings Inc. (NASDAQ: BPTH) is a pioneering biotechnology company focused on developing innovative therapeutic products through its proprietary DNAbilize® technology. This technology enables the delivery of nucleic acid drugs throughout the human body via simple intravenous infusion. Bio-Path's primary focus is on oncology, aiming to provide effective treatments for various forms of cancer.
The company's lead product candidate, prexigebersen (BP1001), is currently in Phase II clinical trials for Acute Myeloid Leukemia (AML) in combination with low-dose cytarabine (LDAC) and decitabine. Additionally, Bio-Path is exploring prexigebersen's potential in combination with dasatinib for patients with blast-phase and accelerated-phase Chronic Myeloid Leukemia (CML).
Another key candidate, BP1002, targets the Bcl-2 protein, which plays a crucial role in cell survival for many cancers. BP1002 is being evaluated for its effectiveness against lymphoma and solid tumors, offering hope for venetoclax-resistant AML patients. The company's technological advantage lies in its DNAbilize® platform, a liposomal antisense DNA method that significantly improves oligonucleotide therapeutics' delivery and efficacy.
Bio-Path Holdings continues to expand its pipeline with additional candidates such as BP1003, a STAT3 antisense oligodeoxynucleotide, and BP1001-A, a modification designed for solid tumors. These developments emphasize the company's commitment to addressing unmet medical needs in oncology.
Recently, Bio-Path has made significant strides in its clinical programs, receiving positive feedback from the U.S. FDA and advancing its trials at renowned institutions including Weill Cornell Medical College and The University of Texas MD Anderson Cancer Center. The company maintains a robust intellectual property portfolio to protect its innovative DNAbilize® platform.
For investors and stakeholders, Bio-Path Holdings represents a forward-thinking entity with a strategic focus on developing novel RNAi nanoparticle drugs. The company's advancements in the clinical and preclinical stages underline its potential to make substantial contributions to cancer treatment paradigms.
Bio-Path Holdings (NASDAQ:BPTH) announced that interim results from its Phase 2 clinical trial of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML) will be presented at the 2024 European Hematology Association (EHA) Congress in Madrid. The data indicates that prexigebersen is well-tolerated and shows compelling efficacy in newly diagnosed and relapsed/refractory AML patients, outperforming frontline therapy. Jorge Cortes, M.D., will present these results on June 14, 2024. Bio-Path develops targeted nucleic acid cancer drugs using its DNAbilize® technology. Their pipeline includes BP1002 for blood cancers and solid tumors and BP1003, for which an IND is expected to be filed.
Bio-Path Holdings (NASDAQ: BPTH) announced that it will present interim data from its Phase 2 clinical trial of prexigebersen for Acute Myeloid Leukemia (AML) at the ASCO Annual Meeting from May 31 - June 4, 2024.
The trial, involving prexigebersen combined with decitabine and venetoclax, showed promising results, demonstrating compelling efficacy and good tolerance in newly diagnosed and refractory/relapsed AML patients.
This presentation aims to highlight the potential of prexigebersen within the oncology community and encourage broader clinical participation.
Details of the presentation include: Title - Interim Safety and Efficacy of BP1001 in a Phase II AML Study, Date - June 1, 2024, Time - 8:00 AM CT, Location - McCormick Place, Abstract Number - 6511.
Bio-Path is also advancing other candidates, BP1001-A and BP1002, for various cancers and plans an IND for BP1003 targeting STAT3.
Bio-Path Holdings (NASDAQ: BPTH) announced its Q1 2024 financial results, marking progress in clinical and corporate milestones. The company strengthened its balance sheet with $3.5 million through share offerings and expanded its global patent portfolio. Key achievements include completing the second dose cohort in its Phase 1/1b trial for BP1002 in AML patients and the first dose cohort for BP1002 in lymphoma and CLL patients.
Financially, Bio-Path reported a net loss of $3.2 million, an improvement from the $5.3 million loss in Q1 2023. R&D expenses decreased to $2.3 million, while G&A expenses slightly increased to $1.4 million. The company had $0.2 million in cash as of March 31, 2024.
Bio-Path Holdings, Inc. will announce its first quarter 2024 financial results on May 15, 2024. The company specializes in developing cancer drugs using its proprietary DNAbilize® antisense RNAi nanoparticle technology. Bio-Path's lead product candidate, prexigebersen, is in Phase 2 study for blood cancers, and BP1001-A is in Phase 1/1b study for solid tumors. The company is also evaluating BP1002 for blood cancers and solid tumors, with an IND expected to be filed for BP1003. Bio-Path will host a live conference call to discuss the financial results and provide a business overview.
FAQ
What is the current stock price of Bio-Path Holdings (BPTH)?
What is the market cap of Bio-Path Holdings (BPTH)?
What is Bio-Path Holdings Inc. known for?
What is DNAbilize® technology?
What is prexigebersen (BP1001)?
What is BP1002 and what does it target?
Which institutions are involved in Bio-Path's clinical trials?
What is the potential advantage of BP1002 over current treatments?
What are the main benefits of DNAbilize® technology for patients?
What is BP1003 and what does it target?
How does Bio-Path Holdings protect its innovations?
How can investors get more information about Bio-Path Holdings?
